Furthermore, PCSK9 inhibitors (PCSK9i) are more often used in patients with dyslipidemia as an adjuvant therapy of statins or monotherapy, and was proved to be able to significantly reduce the risk of arteriosclerotic CV disease (ASCVD).39 This evidence concerns the gene PCSK9 and metabolic syndrome.